At the time when the markets are oscillating like never, health care stock in such situations plays an important role. Few of the stocks which are up and chose to close in green are from the health care sector. Let’s look at them in brief below.
PATRYS LIMITED (ASX: PAB) – The company is under health care and found out that the metastatic triple-negative breast cancer as brain metastases develop in up to 50% of patients and they have devastating effects on neurologic function and its survival. Upon completing a $2.4 million rights issue in February 2018 and a $4.6 million capital raising in May 2018. As at 30 September 2018, Patrys had cash reserves and term deposits of $5.67 million. The stock price surged by 15.385% to $0.030 with the recent announcement of the new product or drug PATDX1. The market capitalization of the stock is $5.85 million at the current price. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]
VOLPARA HEALTH TECHNOLOGIES LIMITED (ASX: VHT) – The company has successful RSNA 2018 for Volpara and Launch of the VolparaLive System and FDA Mandatory Regulations for Breast Cancer Screening. The company wins NZ Health IT International Solution of the Year Award with its recent research. The company had annual recurring revenue (ARR) of NZ $4.84M. With the RSNA momentum behind the company had traditionally strong quarters. There is an increase of 83% compared to HY2018 in the HY revenue from customers sitting at $2.3M. The stock price declined by -1.77% to $1.110 with the restrained profitability.
ONCOSIL MEDICAL LTD (ASX: OSL) – The company is targeting more than $2bn market opportunity to improve the standard of care and has the US FDA-approved IDE in place. With highly experienced management team, strong clinical and commercial pedigree the company is the decent position. The total cash as of September 30, 2018, is A$16.1m with no debt represents that the company has a decent balance sheet. The enterprise value is also healthy at $96.3 million. The stock price traded flat at $0.185 amid the market volatility. At the current prevailing market price, the market capitalization of the company is at $116.68 million.
IMUGENE LIMITED (ASX: IMU) – The company has an experienced board and management and has made successful M&A activity. The cash & equivalents as at 30 Sep 2018 is $23.83 Million. The investment to date ~$42.5M from public and ~$ 5.5M from venture capital. The group’s net assets increased to $15,475,479 compared with the previous year to $11,394,622. As at the end of financial year, the group had cash reserves of $7,822,057 as compared to 2017 of $4,814,200. The group reported a loss for the year ended 30 June 2018 of $3,933,641 as compared to 30 June 2017 of $2,506,571. The stock price traded flat at $0.019 with the loss after expenses on research and development.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.